10x Genomics Yönetim
Yönetim kriter kontrolleri 3/4
10x Genomics CEO'su Serge Saxonov, Jul2012 tarihinde atandı, in görev süresi 12.33 yıldır. in toplam yıllık tazminatı $ 8.29M olup, şirket hissesi ve opsiyonları dahil olmak üzere 6.6% maaş ve 93.4% ikramiyelerden oluşmaktadır. şirketin hisselerinin 3.33% ine doğrudan sahiptir ve bu hisseler $ 69.80M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 2.8 yıl ve 5.4 yıldır.
Anahtar bilgiler
Serge Saxonov
İcra Kurulu Başkanı
US$8.3m
Toplam tazminat
| CEO maaş yüzdesi | 6.6% |
| CEO görev süresi | 12.3yrs |
| CEO sahipliği | 3.3% |
| Yönetim ortalama görev süresi | 2.8yrs |
| Yönetim Kurulu ortalama görev süresi | 5.4yrs |
Son yönetim güncellemeleri
Recent updates
Earnings Update: 10x Genomics, Inc. (NASDAQ:TXG) Just Reported And Analysts Are Trimming Their Forecasts
Nov 01
10x Genomics: Deciphering The Preliminary Q3 Earnings
Oct 12The Price Is Right For 10x Genomics, Inc. (NASDAQ:TXG) Even After Diving 28%
Oct 1110x Genomics Is Still A Long Way From Profitability
Oct 03We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Sep 09Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump
Aug 1010x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead
Jul 1010x Genomics: Sticking To The Plan To Avoid The Falling The Knife
Jun 21Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper
Jun 1410x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business
May 21Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price
Apr 15Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Feb 0510x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses
Jan 20Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%
Dec 22We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely
Nov 03Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation
Aug 04Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S
Jun 04At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?
Apr 2910x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate
Mar 24We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow
Feb 02Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?
Jan 12An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued
Dec 22CEO Tazminat Analizi
| Tarih | Toplam Tazminat | Maaş | Şirket Kazançları |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$183m |
| Jun 30 2024 | n/a | n/a | -US$240m |
| Mar 31 2024 | n/a | n/a | -US$264m |
| Dec 31 2023 | US$8m | US$545k | -US$255m |
| Sep 30 2023 | n/a | n/a | -US$223m |
| Jun 30 2023 | n/a | n/a | -US$172m |
| Mar 31 2023 | n/a | n/a | -US$174m |
| Dec 31 2022 | US$19m | US$504k | -US$166m |
| Sep 30 2022 | n/a | n/a | -US$167m |
| Jun 30 2022 | n/a | n/a | -US$142m |
| Mar 31 2022 | n/a | n/a | -US$89m |
| Dec 31 2021 | US$12m | US$430k | -US$58m |
| Sep 30 2021 | n/a | n/a | -US$455m |
| Jun 30 2021 | n/a | n/a | -US$504m |
| Mar 31 2021 | n/a | n/a | -US$533m |
| Dec 31 2020 | US$11m | US$400k | -US$543m |
| Sep 30 2020 | n/a | n/a | -US$134m |
| Jun 30 2020 | n/a | n/a | -US$78m |
| Mar 31 2020 | n/a | n/a | -US$49m |
| Dec 31 2019 | US$2m | US$394k | -US$31m |
| Sep 30 2019 | n/a | n/a | -US$100m |
| Jun 30 2019 | n/a | n/a | -US$105m |
| Mar 31 2019 | n/a | n/a | -US$105m |
| Dec 31 2018 | US$1m | US$366k | -US$112m |
Tazminat ve Piyasa: Serge 'nin toplam tazminatı ($USD 8.29M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 5.54M ).
Tazminat ve Kazançlar: Serge 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.
CEO
Serge Saxonov (47 yo)
12.3yrs
Görev süresi
US$8,286,050
Tazminat
Dr. Serge Saxonov, Ph D, Co-Founded 10X Genomics, Inc. and has been its Chief Executive Officer and Director since July 2012. Prior to 10x Genomics, Dr. Saxonov was Vice President of Applications at Quanta...
Liderlik Ekibi
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.33% $ 69.8m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 56.2m | |
| Chief Legal Officer | 7.3yrs | US$3.88m | 0.12% $ 2.5m | |
| CFO, Treasurer | less than a year | Veri yok | Veri yok | |
| Chief of Global Operations | less than a year | Veri yok | Veri yok | |
| Founding Scientist & CTO | 2.8yrs | Veri yok | Veri yok | |
| Chief Information Officer | less than a year | Veri yok | Veri yok | |
| Manager of Investor Relations & Strategic Finance | no data | Veri yok | Veri yok | |
| Chief People Officer | 3.8yrs | Veri yok | Veri yok | |
| Chief Commercial Officer | less than a year | Veri yok | Veri yok | |
| Associate Director of Product Management | no data | Veri yok | Veri yok |
2.8yrs
Ortalama Görev Süresi
48.5yo
Ortalama Yaş
Deneyimli Yönetim: TXG 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 2.8 yıldır).
Yönetim Kurulu Üyeleri
| İsim | Pozisyon | Görev süresi | Tazminat | Sahiplik |
|---|---|---|---|---|
| Co-Founder | 12.3yrs | US$8.29m | 3.33% $ 69.8m | |
| Co-Founder | 12.3yrs | US$4.43m | 2.68% $ 56.2m | |
| Independent Director | 4.7yrs | US$338.71k | 0.0038% $ 80.0k | |
| Independent Chairman | 11.3yrs | US$403.59k | 2.02% $ 42.3m | |
| Independent Director | 5.3yrs | US$336.39k | 0.0038% $ 80.0k | |
| Director | less than a year | Veri yok | Veri yok | |
| Independent Director | 5.6yrs | US$346.39k | 0.029% $ 614.6k | |
| Director | less than a year | Veri yok | Veri yok |
5.4yrs
Ortalama Görev Süresi
52yo
Ortalama Yaş
Deneyimli Yönetim Kurulu: TXG 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.4 yıldır).